Global PD-1 and PD-L1 Inhibitors Market 2022-2026

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $2,500	120 Pages	TechNavio	August, 2022	INF17379730

Best Price Guarantee
Price	from $2,500
Length	120 Pages
Publisher	TechNavio
Published Date	August, 2022
SKU	INF17379730

Global PD-1 And PD-L1 Inhibitors Market 2022-2026

Technavio has been monitoring the PD-1 and PD-L1 inhibitors market and it is poised to grow by $ 49.34 bn during 2022-2026, accelerating at a CAGR of 19.31% during the forecast period. Our report on the PD-1 and PD-L1 inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of cancer, the presence of patient assistance programs, and the high target affinity and specificity of pd1 and pdl1 inhibitors.

The PD-1 and PD-L1 inhibitors market analysis includes application segment and geographic landscape.

Technavio's PD-1 and PD-L1 inhibitors market is segmented as below:

By Application

Solid tumors
Blood-related tumors

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the strong pipeline as one of the prime reasons driving the PD-1 and PD-L1 inhibitors market growth during the next few years. Also, strategic alliances and expansion for research areas in pd1 and pdl1 inhibitors will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the PD-1 and PD-L1 inhibitors market covers the following areas:

PD-1 and PD-L1 inhibitors market sizing
PD-1 and PD-L1 inhibitors market forecast
PD-1 and PD-L1 inhibitors market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading PD-1 and PD-L1 inhibitors market vendors that include Akeso Inc., Alphamab Oncology, Amgen Inc., AstraZeneca Plc, BeiGene Ltd., Bristol Myers Squibb Co., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Shanghai Jhunsi Biosciences Ltd. Also, the PD-1 and PD-L1 inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

1 Executive Summary: 1.1 Market overview; Exhibit 01: Executive Summary - Chart on Market Overview; Exhibit 02: Executive Summary - Data Table on Market Overview; Exhibit 03: Executive Summary - Chart on Global Market Characteristics; Exhibit 04: Executive Summary - Chart on Market by Geography; Exhibit 05: Executive Summary - Chart on Market Segmentation by Application; Exhibit 06: Executive Summary - Chart on Incremental Growth; Exhibit 07: Executive Summary - Data Table on Incremental Growth; Exhibit 08: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape: 2.1 Market ecosystem; Exhibit 09: Parent market; Exhibit 10: Market Characteristics
3 Market Sizing: 3.1 Market definition; Exhibit 11: Offerings of vendors included in the market definition; 3.2 Market segment analysis; Exhibit 12: Market segments; 3.3 Market size 2021; 3.4 Market outlook: Forecast for 2021-2026; Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million); Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million); Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%); Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis: 4.1 Five forces summary; Exhibit 17: Five forces analysis - Comparison between 2021 and 2026; 4.2 Bargaining power of buyers; Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026; 4.3 Bargaining power of suppliers; Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026; 4.4 Threat of new entrants; Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026; 4.5 Threat of substitutes; Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026; 4.6 Threat of rivalry; Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026; 4.7 Market condition; Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Application: 5.1 Market segments; Exhibit 24: Chart on Application - Market share 2021-2026 (%); Exhibit 25: Data Table on Application - Market share 2021-2026 (%); 5.2 Comparison by Application; Exhibit 26: Chart on Comparison by Application; Exhibit 27: Data Table on Comparison by Application; 5.3 Solid tumors - Market size and forecast 2021-2026; Exhibit 28: Chart on Solid tumors - Market size and forecast 2021-2026 ($ million); Exhibit 29: Data Table on Solid tumors - Market size and forecast 2021-2026 ($ million); Exhibit 30: Chart on Solid tumors - Year-over-year growth 2021-2026 (%); Exhibit 31: Data Table on Solid tumors - Year-over-year growth 2021-2026 (%); 5.4 Blood-related tumors - Market size and forecast 2021-2026; Exhibit 32: Chart on Blood-related tumors - Market size and forecast 2021-2026 ($ million); Exhibit 33: Data Table on Blood-related tumors - Market size and forecast 2021-2026 ($ million); Exhibit 34: Chart on Blood-related tumors - Year-over-year growth 2021-2026 (%); Exhibit 35: Data Table on Blood-related tumors - Year-over-year growth 2021-2026 (%); 5.5 Market opportunity by Application; Exhibit 36: Market opportunity by Application ($ million)
6 Customer Landscape: 6.1 Customer landscape overview; Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape: 7.1 Geographic segmentation; Exhibit 38: Chart on Market share by geography 2021-2026 (%); Exhibit 39: Data Table on Market share by geography 2021-2026 (%); 7.2 Geographic comparison; Exhibit 40: Chart on Geographic comparison; Exhibit 41: Data Table on Geographic comparison; 7.3 North America - Market size and forecast 2021-2026; Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million); Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million); Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%); Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%); 7.4 Europe - Market size and forecast 2021-2026; Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million); Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million); Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%); Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%); 7.5 Asia - Market size and forecast 2021-2026; Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million); Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million); Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%); Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%); 7.6 Rest of World (ROW) - Market size and forecast 2021-2026; Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million); Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million); Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%); Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%); 7.7 US - Market size and forecast 2021-2026; Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million); Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million); Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%); Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%); 7.8 Germany - Market size and forecast 2021-2026; Exhibit 62: Chart on Germany - Market size and forecast 2021-2026 ($ million); Exhibit 63: Data Table on Germany - Market size and forecast 2021-2026 ($ million); Exhibit 64: Chart on Germany - Year-over-year growth 2021-2026 (%); Exhibit 65: Data Table on Germany - Year-over-year growth 2021-2026 (%); 7.9 Canada - Market size and forecast 2021-2026; Exhibit 66: Chart on Canada - Market size and forecast 2021-2026 ($ million); Exhibit 67: Data Table on Canada - Market size and forecast 2021-2026 ($ million); Exhibit 68: Chart on Canada - Year-over-year growth 2021-2026 (%); Exhibit 69: Data Table on Canada - Year-over-year growth 2021-2026 (%); 7.10 UK - Market size and forecast 2021-2026; Exhibit 70: Chart on UK - Market size and forecast 2021-2026 ($ million); Exhibit 71: Data Table on UK - Market size and forecast 2021-2026 ($ million); Exhibit 72: Chart on UK - Year-over-year growth 2021-2026 (%); Exhibit 73: Data Table on UK - Year-over-year growth 2021-2026 (%); 7.11 France - Market size and forecast 2021-2026; Exhibit 74: Chart on France - Market size and forecast 2021-2026 ($ million); Exhibit 75: Data Table on France - Market size and forecast 2021-2026 ($ million); Exhibit 76: Chart on France - Year-over-year growth 2021-2026 (%); Exhibit 77: Data Table on France - Year-over-year growth 2021-2026 (%); 7.12 Market opportunity by geography; Exhibit 78: Market opportunity by geography ($ million)
8 Drivers, Challenges, and Trends: 8.1 Market drivers; 8.2 Market challenges; 8.3 Impact of drivers and challenges; Exhibit 79: Impact of drivers and challenges in 2021 and 2026; 8.4 Market trends
9 Vendor Landscape: 9.1 Overview; 9.2 Vendor landscape; Exhibit 80: Overview on Criticality of inputs and Factors of differentiation; 9.3 Landscape disruption; Exhibit 81: Overview on factors of disruption; 9.4 Industry risks; Exhibit 82: Impact of key risks on business
10 Vendor Analysis: 10.1 Vendors covered; Exhibit 83: Vendors covered; 10.2 Market positioning of vendors; Exhibit 84: Matrix on vendor position and classification; 10.3 Amgen Inc.; Exhibit 85: Amgen Inc. - Overview; Exhibit 86: Amgen Inc. - Product / Service; Exhibit 87: Amgen Inc. - Key offerings; 10.4 AstraZeneca Plc; Exhibit 88: AstraZeneca Plc - Overview; Exhibit 89: AstraZeneca Plc - Product / Service; Exhibit 90: AstraZeneca Plc - Key news; Exhibit 91: AstraZeneca Plc - Key offerings; 10.5 BeiGene Ltd.; Exhibit 92: BeiGene Ltd. - Overview; Exhibit 93: BeiGene Ltd. - Business segments; Exhibit 94: BeiGene Ltd. - Key offerings; Exhibit 95: BeiGene Ltd. - Segment focus; 10.6 Bristol Myers Squibb Co.; Exhibit 96: Bristol Myers Squibb Co. - Overview; Exhibit 97: Bristol Myers Squibb Co. - Product / Service; Exhibit 98: Bristol Myers Squibb Co. - Key offerings; 10.7 Eli Lilly and Co.; Exhibit 99: Eli Lilly and Co. - Overview; Exhibit 100: Eli Lilly and Co. - Product / Service; Exhibit 101: Eli Lilly and Co. - Key offerings; 10.8 F. Hoffmann La Roche Ltd.; Exhibit 102: F. Hoffmann La Roche Ltd. - Overview; Exhibit 103: F. Hoffmann La Roche Ltd. - Business segments; Exhibit 104: F. Hoffmann La Roche Ltd. - Key news; Exhibit 105: F. Hoffmann La Roche Ltd. - Key offerings; Exhibit 106: F. Hoffmann La Roche Ltd. - Segment focus; 10.9 GlaxoSmithKline Plc; Exhibit 107: GlaxoSmithKline Plc - Overview; Exhibit 108: GlaxoSmithKline Plc - Business segments; Exhibit 109: GlaxoSmithKline Plc - Key news; Exhibit 110: GlaxoSmithKline Plc - Key offerings; Exhibit 111: GlaxoSmithKline Plc - Segment focus; 10.10 Merck and Co. Inc.; Exhibit 112: Merck and Co. Inc. - Overview; Exhibit 113: Merck and Co. Inc. - Business segments; Exhibit 114: Merck and Co. Inc. - Key news; Exhibit 115: Merck and Co. Inc. - Key offerings; Exhibit 116: Merck and Co. Inc. - Segment focus; 10.11 Merck KGaA; Exhibit 117: Merck KGaA - Overview; Exhibit 118: Merck KGaA - Business segments; Exhibit 119: Merck KGaA - Key news; Exhibit 120: Merck KGaA - Key offerings; Exhibit 121: Merck KGaA - Segment focus; 10.12 Sanofi; Exhibit 122: Sanofi - Overview; Exhibit 123: Sanofi - Business segments; Exhibit 124: Sanofi - Key news; Exhibit 125: Sanofi - Key offerings; Exhibit 126: Sanofi - Segment focus
11 Appendix: 11.1 Scope of the report; 11.2 Inclusions and exclusions checklist; Exhibit 127: Inclusions checklist; Exhibit 128: Exclusions checklist; 11.3 Currency conversion rates for US$; Exhibit 129: Currency conversion rates for US$; 11.4 Research methodology; Exhibit 130: Research methodology; Exhibit 131: Validation techniques employed for market sizing; Exhibit 132: Information sources; 11.5 List of abbreviations; Exhibit 133: List of abbreviations
Exhibits:: Exhibits1: Executive Summary - Chart on Market Overview; Exhibits2: Executive Summary - Data Table on Market Overview; Exhibits3: Executive Summary - Chart on Global Market Characteristics; Exhibits4: Executive Summary - Chart on Market by Geography; Exhibits5: Executive Summary - Chart on Market Segmentation by Application; Exhibits6: Executive Summary - Chart on Incremental Growth; Exhibits7: Executive Summary - Data Table on Incremental Growth; Exhibits8: Executive Summary - Chart on Vendor Market Positioning; Exhibits9: Parent market; Exhibits10: Market Characteristics; Exhibits11: Offerings of vendors included in the market definition; Exhibits12: Market segments; Exhibits13: Chart on Global - Market size and forecast 2021-2026 ($ million); Exhibits14: Data Table on Global - Market size and forecast 2021-2026 ($ million); Exhibits15: Chart on Global Market: Year-over-year growth 2021-2026 (%); Exhibits16: Data Table on Global Market: Year-over-year growth 2021-2026 (%); Exhibits17: Five forces analysis - Comparison between 2021 and 2026; Exhibits18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026; Exhibits19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026; Exhibits20: Threat of new entrants - Impact of key factors in 2021 and 2026; Exhibits21: Threat of substitutes - Impact of key factors in 2021 and 2026; Exhibits22: Threat of rivalry - Impact of key factors in 2021 and 2026; Exhibits23: Chart on Market condition - Five forces 2021 and 2026; Exhibits24: Chart on Application - Market share 2021-2026 (%); Exhibits25: Data Table on Application - Market share 2021-2026 (%); Exhibits26: Chart on Comparison by Application; Exhibits27: Data Table on Comparison by Application; Exhibits28: Chart on Solid tumors - Market size and forecast 2021-2026 ($ million); Exhibits29: Data Table on Solid tumors - Market size and forecast 2021-2026 ($ million); Exhibits30: Chart on Solid tumors - Year-over-year growth 2021-2026 (%); Exhibits31: Data Table on Solid tumors - Year-over-year growth 2021-2026 (%); Exhibits32: Chart on Blood-related tumors - Market size and forecast 2021-2026 ($ million); Exhibits33: Data Table on Blood-related tumors - Market size and forecast 2021-2026 ($ million); Exhibits34: Chart on Blood-related tumors - Year-over-year growth 2021-2026 (%); Exhibits35: Data Table on Blood-related tumors - Year-over-year growth 2021-2026 (%); Exhibits36: Market opportunity by Application ($ million); Exhibits37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria; Exhibits38: Chart on Market share by geography 2021-2026 (%); Exhibits39: Data Table on Market share by geography 2021-2026 (%); Exhibits40: Chart on Geographic comparison; Exhibits41: Data Table on Geographic comparison; Exhibits42: Chart on North America - Market size and forecast 2021-2026 ($ million); Exhibits43: Data Table on North America - Market size and forecast 2021-2026 ($ million); Exhibits44: Chart on North America - Year-over-year growth 2021-2026 (%); Exhibits45: Data Table on North America - Year-over-year growth 2021-2026 (%); Exhibits46: Chart on Europe - Market size and forecast 2021-2026 ($ million); Exhibits47: Data Table on Europe - Market size and forecast 2021-2026 ($ million); Exhibits48: Chart on Europe - Year-over-year growth 2021-2026 (%); Exhibits49: Data Table on Europe - Year-over-year growth 2021-2026 (%); Exhibits50: Chart on Asia - Market size and forecast 2021-2026 ($ million); Exhibits51: Data Table on Asia - Market size and forecast 2021-2026 ($ million); Exhibits52: Chart on Asia - Year-over-year growth 2021-2026 (%); Exhibits53: Data Table on Asia - Year-over-year growth 2021-2026 (%); Exhibits54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million); Exhibits55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million); Exhibits56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%); Exhibits57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%); Exhibits58: Chart on US - Market size and forecast 2021-2026 ($ million); Exhibits59: Data Table on US - Market size and forecast 2021-2026 ($ million); Exhibits60: Chart on US - Year-over-year growth 2021-2026 (%); Exhibits61: Data Table on US - Year-over-year growth 2021-2026 (%); Exhibits62: Chart on Germany - Market size and forecast 2021-2026 ($ million); Exhibits63: Data Table on Germany - Market size and forecast 2021-2026 ($ million); Exhibits64: Chart on Germany - Year-over-year growth 2021-2026 (%); Exhibits65: Data Table on Germany - Year-over-year growth 2021-2026 (%); Exhibits66: Chart on Canada - Market size and forecast 2021-2026 ($ million); Exhibits67: Data Table on Canada - Market size and forecast 2021-2026 ($ million); Exhibits68: Chart on Canada - Year-over-year growth 2021-2026 (%); Exhibits69: Data Table on Canada - Year-over-year growth 2021-2026 (%); Exhibits70: Chart on UK - Market size and forecast 2021-2026 ($ million); Exhibits71: Data Table on UK - Market size and forecast 2021-2026 ($ million); Exhibits72: Chart on UK - Year-over-year growth 2021-2026 (%); Exhibits73: Data Table on UK - Year-over-year growth 2021-2026 (%); Exhibits74: Chart on France - Market size and forecast 2021-2026 ($ million); Exhibits75: Data Table on France - Market size and forecast 2021-2026 ($ million); Exhibits76: Chart on France - Year-over-year growth 2021-2026 (%); Exhibits77: Data Table on France - Year-over-year growth 2021-2026 (%); Exhibits78: Market opportunity by geography ($ million); Exhibits79: Impact of drivers and challenges in 2021 and 2026; Exhibits80: Overview on Criticality of inputs and Factors of differentiation; Exhibits81: Overview on factors of disruption; Exhibits82: Impact of key risks on business; Exhibits83: Vendors covered; Exhibits84: Matrix on vendor position and classification; Exhibits85: Amgen Inc. - Overview; Exhibits86: Amgen Inc. - Product / Service; Exhibits87: Amgen Inc. - Key offerings; Exhibits88: AstraZeneca Plc - Overview; Exhibits89: AstraZeneca Plc - Product / Service; Exhibits90: AstraZeneca Plc - Key news; Exhibits91: AstraZeneca Plc - Key offerings; Exhibits92: BeiGene Ltd. - Overview; Exhibits93: BeiGene Ltd. - Business segments; Exhibits94: BeiGene Ltd. - Key offerings; Exhibits95: BeiGene Ltd. - Segment focus; Exhibits96: Bristol Myers Squibb Co. - Overview; Exhibits97: Bristol Myers Squibb Co. - Product / Service; Exhibits98: Bristol Myers Squibb Co. - Key offerings; Exhibits99: Eli Lilly and Co. - Overview; Exhibits100: Eli Lilly and Co. - Product / Service; Exhibits101: Eli Lilly and Co. - Key offerings; Exhibits102: F. Hoffmann La Roche Ltd. - Overview; Exhibits103: F. Hoffmann La Roche Ltd. - Business segments; Exhibits104: F. Hoffmann La Roche Ltd. - Key news; Exhibits105: F. Hoffmann La Roche Ltd. - Key offerings; Exhibits106: F. Hoffmann La Roche Ltd. - Segment focus; Exhibits107: GlaxoSmithKline Plc - Overview; Exhibits108: GlaxoSmithKline Plc - Business segments; Exhibits109: GlaxoSmithKline Plc - Key news; Exhibits110: GlaxoSmithKline Plc - Key offerings; Exhibits111: GlaxoSmithKline Plc - Segment focus; Exhibits112: Merck and Co. Inc. - Overview; Exhibits113: Merck and Co. Inc. - Business segments; Exhibits114: Merck and Co. Inc. - Key news; Exhibits115: Merck and Co. Inc. - Key offerings; Exhibits116: Merck and Co. Inc. - Segment focus; Exhibits117: Merck KGaA - Overview; Exhibits118: Merck KGaA - Business segments; Exhibits119: Merck KGaA - Key news; Exhibits120: Merck KGaA - Key offerings; Exhibits121: Merck KGaA - Segment focus; Exhibits122: Sanofi - Overview; Exhibits123: Sanofi - Business segments; Exhibits124: Sanofi - Key news; Exhibits125: Sanofi - Key offerings; Exhibits126: Sanofi - Segment focus; Exhibits127: Inclusions checklist; Exhibits128: Exclusions checklist; Exhibits129: Currency conversion rates for US$; Exhibits130: Research methodology; Exhibits131: Validation techniques employed for market sizing; Exhibits132: Information sources; Exhibits133: List of abbreviations